Additionally, BRCA Ashkenazi Jewish founder mutations (BRCA1 c.68_69delAG, BRCA1 c.5266_5267insC, or BRCA2 c.5946delT) were detected at similar rates across all subgroups, highlighting the need for further research to understand their role in tumor response to PARP inhibitors [30,31]. Here, BRCA2 is linked to neoplasm.